BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol
Dabrafenib plus trametinib is highly effective in patients with recurrent or progressive BRAF<sup>V600E</sup>-mutated CNS-tumors, representing a valuable therapeutic option for these vulnerable patients.
Authors
- Laurien J. Zeverijn (ORCID: https://orcid.org/0009-0001-1124-7987)
- Antonios Daletzakis (ORCID: https://orcid.org/0000-0002-1151-2250)
- Hans A. J. Gelderblom (ORCID: https://orcid.org/0000-0001-9270-8636)
- Paul Roepman (ORCID: https://orcid.org/0000-0003-1566-0258)
- Birgit S. Geurts (ORCID: https://orcid.org/0009-0007-7205-0890)
- Karlijn Verkerk (ORCID: https://orcid.org/0000-0002-5882-4980)
- Florentine A.J. Verbeek (ORCID: https://orcid.org/0009-0002-7406-8748)
- Henk M.W. Verheul (ORCID: https://orcid.org/0000-0001-5981-922X)
- Wendy W.J. de Leng (ORCID: https://orcid.org/0000-0003-2911-6018)
- Filip Y.F.L. de Vos
- Hans Timmer
- Anne M.L. Jansen
- Emile E. Voest
- Sybren L.N. Maas
- Ilse A.C. Spiekman
- Maud A. van Maren
- Soemeya F. Haj Mohammad
Institutions
- Utrecht University (NL)
- Leiden University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Oncode Institute (NL)
- Cancer Genomics Centre (NL)
- Erasmus MC Cancer Institute (NL)
- Hartwig Medical Foundation (NL)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1016/j.ejca.2026.116674
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00